In a bid to capitalize on the increasing prevalence of cannabis consumption in the US, pharmaceutical companies have introduced a new pill that claims to combat marijuana addiction. The experimental drug, AEF-0117, has shown promise in a small trial by reducing the addictive impact of THC, the primary psychoactive compound in cannabis. While the study published in the journal Nature Medicine may appear encouraging at first glance, a closer examination raises several concerns about the motives behind such pharmaceutical interventions.
The “Justified” star showed up to “Talk Easy” already rejecting the questions, fishing for compliments…
Cone or straight joint? You’ve got a side. Everybody’s got a side. Nobody’s ever had…
From boutique breeder cuts to coral-shaped mutations and potency-tested hybrids, psilocybin mushrooms are evolving into…
Solventless hash is the creme de la creme of cannabis. So why is almost all…
This article originally appeared in High Times’ 50th Anniversary print issue. Get yours here. A…
Researchers looked specifically at participants aged 40 to 70 (average age 54.5) and asked a…